Jessica Birchem, DO
Interventional Cardiology · Springfield, MONPI 1285803353
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Medtronic at 35.7% of the total. 2025 is the largest year on record at $3,267, 6.8 times the $483 reported in 2019.
Across 229 payments — averaging $54.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abiomed$3K
- Edwards Lifesciences$1K
- Amgen$814
- Philips North America LLC$534
- Boston Scientific$481
- plus $2K from 19 others
Across 105 payments — averaging $2972.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$165K
- CSL Behring$103K
- Janssen Research & Development, LLC$32K
- Medtronic$12K
What the payments were for
- Travel & lodging$5,93747%
- Food & beverage$6,55752%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 55 | $4,468 |
| Abiomed | 23 | $2,742 |
| Edwards Lifesciences | 13 | $1,357 |
| Amgen | 31 | $814 |
| Philips North America LLC | 10 | $534 |
| Boston Scientific | 24 | $481 |
| Biotronik Inc. | 4 | $441 |
| Shockwave Medical, Inc | 9 | $416 |
| Cardiovascular Systems Inc. | 15 | $321 |
| Abbott | 8 | $184 |
| Pfizer | 8 | $138 |
| Angiodynamics, Inc. | 2 | $123 |
| Portola Pharmaceuticals, LLC | 1 | $99 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $86 |
| Novartis | 4 | $67 |
| ZOLL Circulation Inc | 3 | $62 |
| Penumbra, Inc. | 4 | $47 |
| Sensible Medical Innovations Inc | 1 | $21 |
| Terumo Medical Corporation | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $14 |
| Atricure, Inc. | 1 | $12 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,506 in reported general payments places this provider in the 55th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 455 | $419,931 |
| EntrestoSacubitril/Valsartan | 219 | $230,178 |
| XareltoRivaroxaban | 165 | $150,550 |
| Repatha SureclickEvolocumab | 150 | $118,259 |
| JardianceEmpagliflozin | 38 | $35,506 |
| BrilintaTicagrelor | 24 | $17,703 |
| Praluent PenAlirocumab | 20 | $16,632 |
| FarxigaDapagliflozin Propanediol | 21 | $12,479 |
| Ranolazine ErRanolazine | 89 | $6,145 |
| Prasugrel Hcl | 43 | $4,619 |
| Metoprolol Succinate | 568 | $4,150 |
| Atorvastatin Calcium | 672 | $4,005 |
| Flecainide Acetate | 118 | $3,715 |
| ClopidogrelClopidogrel Bisulfate | 461 | $3,315 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 544 | $3,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $138 | $419,931455 claims |
| NovartisEntresto | $67 | $230,178219 claims |
| Boehringer IngelheimJardiance | $14 | $35,50638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Springfield
- Philipp WiesnerSpringfield$47K
- Amod AmritphaleSpringfield$19K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.